Zanamivir

From Proteopedia

Revision as of 11:14, 12 December 2010 by David Canner (Talk | contribs)
Jump to: navigation, search

Zanamivir, better known as Relenza, ([[____]])

Drag the structure with the mouse to rotate

Better Known as: Relenza

  • Marketed By: GlaxoSmithKline
  • Major Indication: Influenza Infection
  • Drug Class: Neuraminidase Inhibitor
  • Date of FDA Approval:
  • 2009 Sales:$1.1 Billion
  • Importance:
  • See Pharmaceutical Drugs for more information about other drugs and diseases.

Mechanism of Action

Pharmacokinetics

Neuraminidase Inhibitor Pharmacokinetics
Parameter Zanamivir Oseltamivir
Tmax (hr) 1.25 1.5
Cmax (ng/ml) 31.6 57
Bioavailability (%) 2 75
Protein Binding (%) 10 42
T1/2 (hr) 3 3.2
AUC (ng/ml/hr) 185 204
Clearance (L/h) 54.1 18.8
Dosage (mg) 10 300
Metabolism None Hepatic

For References to Pharmacokinetic data, see: References

References


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

Retrieved from "http://52.214.119.220/wiki/index.php/Zanamivir"
Personal tools